生物技术

A New Turning Point in Biotechnology Innovation: Global Market Restructuring Driven by Synthetic Biology and Precision Medicine by 2025

Editor
7 分钟阅读

As of the end of 2025, the global biotechnology industry is charting a new growth trajectory amidst an unprecedented wave of innovation. According to the latest report from the McKinsey Global Institute, the global biotechnology market size is expected to reach approximately $2.4 trillion by 2025, with an average annual growth rate of 15.3%. The key drivers of this growth are the rapid technological advancements in the fields of Synthetic Biology and Precision Medicine, fundamentally altering the traditional paradigm of drug development. Notably, the market share in the Asia-Pacific region surged from 23% in 2024 to 27% in 2025, indicating the prominence of biotech companies from South Korea and China in the global competition.

A New Turning Point in Biotechnology Innovation: Global Market Restructuring Driven by Synthetic Biology and Precision Medicine by 2025

South Korea’s biotechnology ecosystem has achieved remarkable milestones in 2025. Samsung Biologics, headquartered in Incheon, recorded a 34% increase in revenue to 2.8 trillion won in the third quarter of 2025 compared to the same period last year, further solidifying its dominant position in the global Contract Development and Manufacturing Organization (CDMO) market for biopharmaceuticals. The company secured new contracts worth a total of $4.7 billion in the first half of this year alone, with 78% related to the production of mRNA vaccines and Antibody-Drug Conjugates (ADCs). With the full operation of its fourth plant in Songdo, Incheon, Samsung Biologics currently possesses an annual biopharmaceutical production capacity of 364,000 liters, significantly surpassing Switzerland’s Lonza at 280,000 liters and Germany’s Boehringer Ingelheim at 200,000 liters.

Celltrion is also experiencing strong growth in the biosimilar market in 2025. The company, based in Incheon, achieved $1.2 billion in sales in the U.S. market alone through its FDA-approved bevacizumab biosimilar ‘Vegaly’. Notably, Celltrion’s next-generation antibody platform technology has improved production efficiency by 40% compared to existing methods, significantly enhancing the price competitiveness of biosimilars. The global biosimilar market is estimated to be worth $58 billion by 2025 and is projected to grow at an average annual rate of 13.8% to reach $110 billion by 2030.

The Synthetic Biology Revolution and Market Restructuring

The field of synthetic biology has emerged as a new growth engine for the biotechnology industry, entering the stage of commercial practicality in 2025. Ginkgo Bioworks, headquartered in Boston, USA, recorded $120 million in revenue in the third quarter of this year, an 89% increase from the same period last year, primarily driven by the surge in demand for customized microbial design services. The company’s automated biological design platform currently has the capability to test over 100,000 genetic circuits daily, reducing development time by an average of 65% compared to traditional R&D methods.

Innovative advancements are also continuing in the field of precision medicine. Gilead Sciences, headquartered in Foster City, California, achieved $4.6 billion in revenue through its CAR-T cell therapies ‘Yescarta’ and ‘Tecartus’ in 2025, a 28% increase from the previous year. The company’s next-generation CAR-T platform significantly improved the complete remission rate from 73% to 89% compared to existing therapies. The global cell therapy market is expected to be worth $19 billion by 2025 and is projected to grow at an average annual rate of 22.4% to reach $52 billion by 2030.

Roche, headquartered in Basel, Switzerland, has established a unique position in the field of personalized medicine. Through its Foundation Medicine subsidiary, the company processes over 250,000 comprehensive genomic profiling (CGP) tests annually as of 2025, a 35% increase from the previous year. Roche’s personalized medicine portfolio recorded a total of $14.2 billion in revenue this year, with the oncology segment accounting for 78%. Notably, the company’s HER2-positive breast cancer treatment ‘Herceptin Deruxtecan’ demonstrated a 28% extension in disease-free survival compared to existing Herceptin, proving the effectiveness of personalized treatment.

Meanwhile, Novartis maintains a leading position in the field of gene therapy. The company, headquartered in Basel, Switzerland, achieved $1.8 billion in revenue through its spinal muscular atrophy (SMA) treatment ‘Zolgensma’ in 2025, recognized as a commercial success case for a gene therapy that can be cured with a single dose. Zolgensma’s treatment success rate is over 95%, showing a long-term cost-effectiveness advantage over the existing standard treatment, Spinraza (annual cost of $400,000). The global gene therapy market is expected to be worth $8.5 billion by 2025, with an average annual growth rate of 34.5% to reach $36 billion by 2030.

Global Competitive Landscape and Investment Trends

The global investment patterns in the biotechnology sector in 2025 show a clear shift. According to the latest analysis by PwC, global biotech venture capital investment totaled $24.7 billion this year, an 18% increase from the previous year, with Asia accounting for a record high of 32%. Notably, South Korean biotech startups received a total of $3.4 billion in investment, a 156% increase from the previous year. This surge in investment is largely attributed to the high global clinical trial success rate of K-bio companies, which stands at 68%, significantly exceeding the global average of 52%.

Pfizer, headquartered in New York, USA, is focusing on developing next-generation vaccines using mRNA platform technology in 2025. The company invested $4.5 billion in mRNA research and development in the first half of this year alone, accounting for 38% of its total R&D budget. Notably, Pfizer’s universal influenza vaccine under development showed an antibody response rate of over 95% in Phase 2 clinical trials, three times more effective than existing seasonal flu vaccines. Based on these achievements, Pfizer’s vaccine division recorded $18.9 billion in revenue in 2025, a 23% increase from the previous year.

Johnson & Johnson is also expanding its market dominance through the development of innovative immuno-oncology drugs. The company, headquartered in New Brunswick, New Jersey, has established a unique position in the treatment of multiple myeloma through combination therapies based on the CD38-targeted antibody ‘Daratumumab’. Daratumumab-related revenue reached $6.7 billion in 2025, accounting for 42% of the global multiple myeloma treatment market. Notably, the company’s subcutaneous Daratumumab administration reduces administration time by 90% compared to intravenous injection while maintaining equivalent therapeutic efficacy, significantly contributing to patient convenience and healthcare cost savings.

Chinese biotech companies are also expanding their presence in the global competition. BeiGene, headquartered in Shanghai, recorded $2.8 billion in revenue in the U.S. and European markets through its BTK inhibitor ‘Brukinsa’, a 67% increase from the previous year. Brukinsa achieved rapid market share expansion based on clinical results showing a 40% reduction in side effects compared to the first-generation BTK inhibitor, Ibrutinib, while maintaining equivalent therapeutic efficacy. The market share of Chinese companies in the global hematologic cancer treatment market is expected to be 12% by 2025, up significantly from 3% in 2020.

The future outlook for the biotechnology industry is positive in many aspects. The introduction of artificial intelligence and machine learning technologies is continuously improving the success rate of new drug development, expected to increase from the current 15% to 25% by 2030. Additionally, the spread of personalized medicine is expected to enhance treatment efficacy while reducing side effects. The aging population and increased healthcare spending in the Asia region provide new growth opportunities for biotech companies. In South Korea, the population aged 65 and over is expected to account for 18.4% of the total population by 2025, with healthcare spending reaching 8.9% of GDP, supporting the sustained growth of the biotech market.

However, several challenges also exist. Increasing complexity in regulatory environments, rising clinical trial costs, and global supply chain instability are cited as major risk factors. Particularly, as FDA and EMA approval standards become more stringent, the average drug development period is extended to 12-15 years, with total development costs increasing to an average of $2.8 billion. In this environment, biotech companies must secure competitiveness through efficient capital allocation and strategic partnerships. As of the end of 2025, the global biotechnology industry is finding a new balance between opportunities for technological innovation and market expansion and challenges of regulatory tightening and increased development costs, which are expected to significantly reshape the industry landscape over the next five years.

*This analysis is based on publicly available market data and industry reports, and additional due diligence is required for investment decisions. Actual financial performance and market data of the mentioned companies should be verified through official announcements.*

#SamsungBiologics #Celltrion #GileadSciences #Roche #Novartis #Pfizer #Johnson&Johnson

Editor

Leave a Comment

Related Articles

生物技术产业的AI融合革命:2025年新药开发与精准医学市场展望

人工智能与生物技术的融合正在从根本上改变新药开发的范式。到2025年,基于AI的新药开发市场同比增长42%,达到180亿美元,传统制药行业的研发流程正在被创新性地重组。

生物技术产业的新转折点:2026年AI融合与个性化治疗市场趋势分析

2026年,生物技术产业正经历历史上最为动态的变化,三大趋势同时进行:与人工智能的融合、个性化治疗的商业化以及下一代生物制造平台的普及。根据麦肯锡的最新报告,全球生物技术市场在2026年已增长至1.24万亿美元,比前一年增长了18.5%。尤其值得注意的是,基于AI的新药开发市场单独形成了890亿美元的规模,占整个生物技术投资的32%。这种增长不仅仅是技术进步,还意味着整个生物产业的范式转变,传统制药公司与新兴生物技术企业之间的界限正在迅速模糊。 韩国的生物技术生态系统在2026年表现尤为显著。位于仁川松岛的三星生物制剂公司在今年第一季度实现了8,950亿韩元的销售额,同比增长24%,这大大提升了韩国企业在全球CDMO(合同开发与制造组织)市场的地位。特别是三星生物制剂公司最近与美国Moderna签订的mRNA疫苗生产合同预计将在未来五年内带来约2万亿韩元的销售额。同时,总部位于仁川的Celltrion在生物仿制药领域保持着独特的地位,2026年上半年实现了1.32万亿韩元的销售额。这是因为其抗癌生物仿制药产品在欧洲和美国的市场份额持续扩大。 AI与生物技术的融合是2026年最受关注的趋势之一,推动了新药开发过程的全面创新。自英国伦敦的DeepMind的AlphaFold技术商业化以来,蛋白质结构预测领域取得了惊人的进展。目前,全球主要制药公司的78%已采用基于AI的新药开发平台,通过此平台将平均新药开发周期从原来的12-15年缩短至8-10年。位于美国加州旧金山的Genentech宣布,通过AI设计的抗体平台,仅在2026年就获得了15个新的管线。这种基于AI的方法不仅提高了开发速度,还使得对以前不可能的靶点的药物开发成为可能。 个性化治疗市场的爆炸性增长 Kymriah和Breyanzi是由不同公司开发的CAR-T疗法,用于特定的复发性或难治性B细胞恶性肿瘤。FDA资料显示,Kymriah属于Novartis,Breyanzi属于Bristol Myers Squibb旗下的Juno Therapeutics。CAR-T治疗也存在严重风险,因此不能概括为能够治愈所有血液癌症。 EDIT-101在14名LCA10患者中开展的是1/2期试验。Editas的申报文件称,在2022年11月的分析中,14人中有3人达到公司设定的复合反应标准,公司于2023年1月暂停继续招募。随后发表的2024年同行评议论文报告,14人中有11人在四项结局指标中的至少一项达到具有临床意义的改善,6人在至少两项指标上达到这一标准。由于不同指标的结果并不相同,不能把该研究表述为2期或3期试验,也不能概括为73%或87%的统一视力改善率。 亚洲地区,特别是中国和日本的个性化治疗市场增长显著。总部位于中国上海的WuXi AppTec通过个性化细胞治疗CDMO业务在2026年上半年实现了28亿美元的销售额,同比增长45%。在日本,京都大学iPS细胞研究所相关的多个生物创业公司在iPS细胞基础的再生治疗开发中取得了显著成果。特别是位于日本大阪的Healios宣布,其利用iPS细胞来源的神经干细胞治疗中风的药物HLCN061在二期临床试验中确认了显著效果。 生物制造平台的创新与竞争格局 生物制造领域在2026年经历了自动化、连续生产和数字孪生技术的引入带来的根本性变化。从传统的批量生产方式向连续生产方式的转变正在加速,通过此方式生产效率平均提高了40%,成本降低了25%。总部位于美国新泽西州的强生公司Janssen部门在比利时Beerse的新设施中引入了连续生产方式,将单克隆抗体生产成本降低了35%。该设施具备每年生产2,000公斤抗体的能力,在30%更少的空间内实现了与现有设施相同的生产量。 数字技术在生物制造中的引入在质量控制和工艺优化方面带来了创新性变化。总部位于德国达姆施塔特的Merck KGaA在其生物制造设施中引入了基于AI的工艺分析技术(PAT,Process Analytical Technology),实现了实时质量监控和预测性维护。通过此技术,批次失败率从原来的3.2%大幅降低至0.8%,整体生产效率提高了28%。在韩国,三星生物制剂在仁川第三工厂引入的智能工厂系统备受关注。该系统整合了IoT传感器、AI分析和自动化机器人,建立了最小化人类干预的无人生产线,从而提高了22%的生产力,并减少了85%的人为错误。 生物制造领域的竞争格局在2026年变得更加激烈。现有的大型CDMO企业与新兴平台企业之间的竞争加剧,特别是下一代治疗类型的生产能力成为核心竞争要素。总部位于瑞士巴塞尔的Lonza大幅扩展了mRNA、细胞与基因治疗以及ADC(抗体-药物偶联物)的生产能力,预计在2026年仅此领域就将实现45亿美元的销售额。这相当于总销售额的67%,反映了下一代治疗市场的快速增长。 亚洲地区作为生物制造中心的地位也大大增强。特别是新加坡在政府的积极支持下建立了生物制造集群,截至2026年,已有12个主要生物制造设施在运营。新加坡政府宣布计划到2030年在生物制造领域投资总计200亿美元,以此推动成为亚太地区的生物制造中心。韩国也通过K-生物带项目在仁川、五松和大邱地区建立了生物集群,截至2026年,已有340家生物企业集中于此。 从生物技术产业的投资趋势来看,2026年是以选择性投资和战略合作伙伴关系为主的年份。根据PitchBook的分析,2026年上半年全球生物技术投资规模为340亿美元,同比下降8%,但平均投资规模为1.23亿美元,增长了23%。这表明投资者更加关注拥有成熟技术和明确商业化路径的企业。特别是对拥有AI基础新药开发平台的企业的投资集中,仅此领域就投入了89亿美元。…

生物制药行业的AI创新:2026年数字新药开发的新转折点

人工智能和机器学习对生物制药行业的颠覆性创新在2026年进入了全面商业化阶段。全球基于AI的新药开发市场迅速增长至230亿美元,根本性地重塑了传统制药公司与生物技术初创企业之间的竞争格局。